A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of SJP-001 in Comparison With Fexofenadine and Naproxen Administered in Conjunction With Alcohol.

Sen-Jam Pharmaceutical1 个研究点分布在 1 个国家目标入组 47 人开始时间: 2025年9月30日最近更新: 2026年3月23日

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 47
试验地点: 1
主要终点: Pharmacokinetics (PK) of two different doses of SJP001 administered in conjunction with alcohol to healthy adult subjects- Cmax (Maximum plasma concentration)

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (SJP-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The amount of alcohol may vary from subject to subject, however each subject will consume the same types and amounts of alcohol on each subsequent treatment day as consumed on the first.

详细描述

At each of four treatment visits, each separated by a minimum 7-day washout (i.e., the treatment day followed by a minimum of 6 subsequent non-treatment days), subjects will be administered SJP-001, placebo, fexofenadine alone and naproxen alone. Subjects will be randomized equally to one of four treatment sequences, according to a schedule prepared prior to the start of the study. Treatments will be administered 15 minutes before the start of a maximum 3-hour interval during which subjects will drink their choice of a selection of alcoholic and non-alcohol beverages. The amount of alcohol consumed will be targeted to achieve a breath alcohol content (BrAC) of 0.08%, a level estimated to be sufficient to produce a hangover the following day.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy men or women between 18 and 65 years inclusive.
•Good general health as determined by a thorough medical history and physical examination including vital signs. Repeat testing at Screening is acceptable for out- of range vital signs.
•Subject is a self-reported moderate drinker of alcohol, sometimes or regularly consuming 2 to 7 units of alcohol. Moderate drinking can be approximated with a BAC of 0.04 -0.11%. The 0.04% - 0.11% BAC correlates approximately with a 54-72 kg female drinking 2 to 5 drinks in 2 to 3 hours, respectively, and a 72-95 kg male drinking 3 to 7 drinks in 2 to 3 hours, respectively.
•Subject has prequalified as likely hangover-sensitive based on pre-study questionnaire.
•Body mass index between 18 and 32 kg/m2, inclusive.
•Report a regular, habitual bedtime between 21:30 and 24:
•Females of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test upon admission for each treatment visit and be using an acceptable method of contraception.
•Subject is capable of understanding the requirements of the study and to give written informed consent.
•Subject is able to follow study instructions and is willing to complete all study visits and procedures.

排除标准

•Acute illness within 14 days prior to screening visit.
•Allergic reaction within 7 days of screening visit.
•Vaccination administration within 7 days of screening visit.
•Clinically significant, unstable medical illness.
•AST, ALT or Bilirubin value greater than >1.5x ULN. Repeat testing at Screening is acceptable for out-of-range values following approval by the PI or designees.
•Estimated glomerular filtration rate (eGFR) < 80 mL/min (determined with an appropriate method by the reporting laboratory). Repeat testing at Screening is acceptable for out-of-range values following approval by the PI or designees.
•Prothrombin time > 1.3(s). Repeat testing at Screening is acceptable for out-of-range values following approval by the PI or designees.
•Any abnormal laboratory value considered by the investigator to be clinically significant.
•Evidence or history of clinically significant autoimmune, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic or neurological disease that would make implementation of the protocol or interpretation of the study results difficult, or that would put the subject at risk by participating in the study in the opinion of the Investigator.
•History of cancer or diabetes, (excluding subjects with resected basal cell carcinoma and squamous cell carcinoma at the discretion of the PI).
•Subject has a previous or current Substance-Related Disorder as defined by DSM-
•A score of 8 or greater on the AUDIT scale.
•Self-report of recent (within one month) or current use of smoked or chewed tobacco products, or use of nicotine (e.g., nicotine gum or patch).
•Positive alcohol Breathalyzer test at screening or check-in for any treatment visit.
•Positive urine drug screen at screening or at check-in for any treatment visit.
•Systolic blood pressure (BP) outside the range of 100 and 140 mmHg, diastolic BP outside the range of 50 and 90 mmHg, at Screening. For the purpose of qualifying any given participant for study participation, out-of-range vital signs may be repeated once.
•Heart rate > 100 beats per minute at screening.
•Subjects who are unwilling to forgo caffeine consumption with or following dinner on each treatment night or who are unwilling to comply with study restrictions for prohibited medications/ foods throughout study participation.
•Clinically significant psychiatric illness, including chronic psychiatric illness or the history or presence of any Axis I condition, including anxiety and/or depression within the past 6 months).
•Any clinically significant abnormal finding on physical examination or vital signs.
•Subject has previously experienced an allergic reaction or adverse event associated with aspirin, NSAIDs, or antihistamine usage.
•Subject requires the use of any prescription medication 14 days prior to day 1, over the counter (OTC) oral pain medication(s) 7 days prior to first dose (paracetamol, oral contraceptives and vitamins are permissible), or any prescription medication or over the counter medication on the day of dosing during the study (oral contraceptives are permissible). This includes use during previous treatment periods during the study.
•Women who are breastfeeding.
•Any medical condition or any condition or situation that in the investigator's opinion may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
•Concurrent participation in an investigational drug or device study, or use of any investigational drug within 30 days prior to screening.
•Participant is unwilling to refrain from strenuous exercise (including weightlifting) 24 hours prior to admissions.
•Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to admission.

结局指标

主要结局

Pharmacokinetics (PK) of two different doses of SJP001 administered in conjunction with alcohol to healthy adult subjects- Cmax (Maximum plasma concentration)